Our findings suggest that a relatively simple and easy to use method based on DXA studies can provide useful data on properties of the Hip in clinical practice.
J Bone Miner Res June; 31(6):1167-1176 . doi: 10.1002/jbmr.2797. Epub 2016 Jan 28. In conclusion, our identification of a novel germline gain-of-function Gα11 mutation, Val340Met, causing ADH2 demonstrates the importance of the Gα11 C-terminal region … Leer más
J Clin Endocrinol Metab. 2016 Jun;101(6):2273-83. doi: 10.1210/jc.2015-3907. Epub 2016 Mar 4. CONCLUSIONS: This document not only provides a summary of our current knowledge but also places recent advances in its management into a context … Leer más
N Engl J Med. 2016 Jun 30;374(26):2553-62. doi: 10.1056/NEJMoa1509342. CONCLUSIONS: Our study showed that Pyle’s disease was caused by a deficiency of sFRP4, that cortical-bone and trabecular-bone homeostasis were governed by different mechanisms, and that … Leer más
Osteoporos Int. 2016 Jun;27(6):1953-66. doi: 10.1007/s00198-015-3468-4. Epub 2016 Jan 18. Hip, whole body and femoral neck BMD were reduced to a statistically significant level in AN but not BN groups. The meta-regression was limited by … Leer más
Calcif Tissue Int. 2016 Jun;98(6):546-55. doi: 10.1007/s00223-015-0105-3. Epub 2016 Jan 9. The variability in values generated from Biomedica, R&D Systems and TECOmedical assays raises questions regarding the accuracy and specificity of the assays. Direct comparison … Leer más
Local activation of 1α-hydroxylase in the artery mediates vascular calcification observed in uremia
These results demonstrate the chondroprotective effects of the combination chondroitin sulfate-glucosamine in vivo, in the experimental model of anterior cruciate ligament transection in ovariectomised rats, and suggest that this combination may be useful to control … Leer más
Novel osteoinductive biphasic calcium phosphate particles demonstrate a wide range of significant increases over several key molecules implicated in osteogenesis that may be implicated in their ability to form ectopic bone formation.
One in two real-life users of alendronate exhibited one or more clinical characteristics that would have led to them being excluded from the FIT trial.
